---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-26-000041"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:52:00.774298+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Travere Q1 net product sales up 64% to $124.5M; FILSPARI approved for FSGS

## Summary
- FILSPARI net sales $105.2M (+88% YoY); 993 new PSFs in IgAN during Q1.
- FDA approved FILSPARI for FSGS on April 13; first patients treated within a week.
- Net loss $37.1M ($0.40/sh) vs $41.2M ($0.47/sh); non-GAAP net income $4.1M ($0.05/sh).
- Phase 3 HARMONY of pegtibatinase restarted; first new patient dosed; topline data due 2H 2027.
- Cash & equivalents $264.7M as of March 31; $25M milestone from Mirum received in April.

## SEC filing metadata
- accession: 0001438533-26-000041
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/0001438533-26-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/tvtx-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-26-000041
- JSON: https://secwatch.observer/filing/0001438533-26-000041.json
- Plain text: https://secwatch.observer/filing/0001438533-26-000041.txt

## Key facts
- Earnings Releases
  Travere Therapeutics, Inc. reported the quarter ended March 31, 2026 results: revenue $124.5 million, net income Net loss for the first quarter of 2026 was $37.1 million, or $0.40 per basic share, EPS $0.40 per basic share.
  - Period: the quarter ended March 31, 2026
  - Revenue: $124.5 million
  - Net income: Net loss for the first quarter of 2026 was $37.1 million, or $0.40 per basic share
  - EPS: $0.40 per basic share
  - Result: reported results
  source text: supporting a compelling long-term trajectory for the Company.” Financial Results for the Quarter Ended March 31, 2026 U.S. net product sales for the first quarter of 2026 were $124.5 million, compared to $75.9 million for the same period in 2025. The increase is attributable to growth in sales of FILSPARI. Research and development (R&D) expenses for the first quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/0001438533-26-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.